3.21
-2.17 (-40.32%)
| Penutupan Terdahulu | 5.37 |
| Buka | 3.00 |
| Jumlah Dagangan | 2,494,729 |
| Purata Dagangan (3B) | 1,638,256 |
| Modal Pasaran | 302,706,496 |
| Harga / Pendapatan (P/E Ke hadapan) | 54.05 |
| Harga / Jualan (P/S) | 0.610 |
| Harga / Buku (P/B) | 1.53 |
| Julat 52 Minggu |
| Margin Keuntungan | -12.20% |
| Margin Operasi (TTM) | -14.80% |
| EPS Cair (TTM) | -1.12 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -3.10% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 22.36% |
| Nisbah Semasa (MRQ) | 1.90 |
| Aliran Tunai Operasi (OCF TTM) | -6.40 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 18.68 M |
| Pulangan Atas Aset (ROA TTM) | -5.26% |
| Pulangan Atas Ekuiti (ROE TTM) | -13.84% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Diagnostics & Research (US) | Bercampur | Menaik |
| Diagnostics & Research (Global) | Bercampur | Menaik | |
| Stok | Myriad Genetics, Inc. | Bercampur | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 3.0 |
| Purata Bergerak Teknikal | -2.5 |
| Osilator Teknikal | -2.5 |
| Purata | -0.67 |
|
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual’s risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services. |
|
| Sektor | Healthcare |
| Industri | Diagnostics & Research |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 2.77% |
| % Dimiliki oleh Institusi | 104.21% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |